SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending following its Q4 delivery report, which indicated vehicle delivery figures below market expectations. While some investors see the miss as already priced in and highlight record energy storage deployments, the community remains divided. The ongoing debate centers on the company's core automotive business grappling with declining sales in key European markets versus its long-term potential in AI, robotics, and new ventures, alongside discussions of a potential SpaceX IPO.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is actively trending as the community discusses its recently finalized acquisition of Ask Sage, a strategic move bolstering its secure generative AI capabilities for defense and regulated sectors. Investors are closely watching for contract announcements and debating the significance of a pending share authorization vote, with many drawing parallels to the growth trajectory of Palantir in the government AI space.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

Nio is trending as record December and Q4 delivery numbers, alongside approaching one million cumulative vehicle deliveries, are sparking renewed optimism among investors. While many anticipate potential Q4 profitability and a market re-evaluation given the strong performance and growing battery swap network, a significant portion of the community expresses frustration over persistent stock manipulation preventing sustained price appreciation.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is currently trending as its AI chip unit, Kunlunxin, filed for a Hong Kong IPO, drawing significant investor enthusiasm for China's domestic AI technology. The community is buzzing over the potential for Baidu's AI capabilities, with discussions highlighting claims that Kunlunxin chips are being adopted by prominent AI models. This development reinforces Baidu's strategic positioning to capitalize on the country's push for semiconductor independence and its broader expansion in the AI sector.

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

Ironwood Pharmaceuticals is seeing significant interest after providing exceptionally strong 2026 financial guidance, far exceeding market expectations for both revenue and EBITDA, driven by robust LINZESS sales projections. The community is actively discussing the company's clear undervaluation and high institutional ownership, fueling anticipation for a potential acquisition amidst the current surge in biotech M&A activity.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending due to notable pre-market activity in its warrants, igniting community speculation that a significant catalyst or "launch" could be imminent. Many investors believe the stock is severely undervalued with robust contracts and a tight float, anticipating a potential short squeeze as tax-loss selling concludes. However, some express frustration over perceived past communication issues from management, fueling a debate over whether current price action reflects manipulation or deeper concerns for the AI sector company.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is actively trending as a low-float biotech company, with community discussion centered on its ongoing strategic review for potential mergers or acquisitions following a pipeline discontinuation. The company's substantial cash reserves relative to its market cap, combined with an extremely tight share float, are fueling intense speculation for a major short squeeze and parabolic price movement. Traders are keenly observing for catalysts while acknowledging the inherent high volatility of such plays.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe Coin is experiencing significant trending interest amid price volatility, sparking a lively debate between optimistic holders hoping for "zero-dropping" gains and strong skeptics calling it a "scam" or "garbage." The community is buzzing with hopes for substantial upward movement, often linking its potential to a broader meme crypto rally, despite widespread warnings about its past performance and current price levels.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

Alchemy Investments Acquisition Corp 1 (ALCY) is trending due to anticipation surrounding its pending merger with Cartiga, described as a profitable company with a strong business model. The community is heavily focused on its extremely low float, drawing comparisons to recent high-flying SPACs and anticipating a substantial short squeeze. Many traders are actively positioning themselves, expecting significant upside as part of a broader low-float "shell company" trend.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending due to significant community division ahead of its upcoming shareholder meeting, where a contentious proposal to vastly increase authorized shares is being debated. Many investors express frustration and anger over perceived share dilution and the stock's underperformance relative to Ethereum, while long-term optimists view current price levels as a buying opportunity, banking on the company's substantial Ethereum holdings and future staking revenue.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Santa Rally Falls Short: Top ETF Performers of December

Santa Rally fizzled as markets stumbled, but ETFs tied to cannabis (MSOS, WEED), metals (SLV, PPLT) and space (UFO) surged.

Top & Flop ETF Areas of 2025

Silver, gold & platinum ETFs (SLVP, SILJ, GOEX) crushed it in 2025, while MSOS, MEME & VIXY lagged amid policy, hype & calm markets.

<ul class="summary-bullets"><li>Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.&nbsp;</li><li>The executive order directs Trump’s administration to initiate the steps needed for the classification shift.</li></ul><p>Shares of Tilray Brands, Aurora Cannabis and Trulieve Cannabis pulled back on Thursday after an early rally sparked by U.S. President Donald Trump’s executive order to ease federal restrictions on marijuana lost momentum, as investors pared gains following the initial reaction to the policy move.</p><p>Shares of TLRY and ACB fell 5% and 3% respectively at the time of writing while TCNNF dropped 17%.&nbsp;</p><h2 class="st-heading-2">Trump Pushes Medical Marijuana</h2><p>President Donald Trump on Thursday signed an executive order to reschedule marijuana to make it less restrictive and available for “legitimate medical uses.”</p><p>Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research. Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.</p><p>“We have people begging for me to do this, people that are in great pain for decades,” Trump said while referring to patients suffering from extreme pain and incurable diseases including cancer. The executive order directs Trump’s administration to initiate the steps needed for the classification shift.</p><p>“Schedule III status will allow research studies to incorporate real-world evidence and models that can assess the health outcomes of medical marijuana and legal CBD products while focusing on long-term health effects in vulnerable populations like adolescents and young adults,” the White House said in a statement.</p><p>State regulations on cannabis are currently complex. While a few U.S. states currently permit the recreational use of cannabis, some allow it for medical purposes.</p><h2 class="st-heading-2">How Did Trump Decide?</h2><p>According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-18/trump-signs-order-to-reclassify-marijuana-in-industry-win">report</a> from Bloomberg, Trump came to the decision following discussions with Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid Services Administrator Mehmet Oz as well as cannabis-industry leaders including Trulieve Cannabis Corp CEO Kim Rivers. As per the report, the Centers for Medicare &amp; Medicaid Services is also expected to complete a plan to test making some Medicare patients eligible for therapies derived from cannabinoids.</p><p>Jazz Pharmaceuticals’ Epidiolex is currently the only drug approved by the U.S. Food and Drug Administration composed of CBD, a psychoactive compound found in cannabis.</p><h2 class="st-heading-2">Tilray Plans Expansion With Trump’s Push</h2><p>Tilray, a producer and distributor of medical and adult-use cannabis, subsequently confirmed plans to advance its U.S. medical cannabis operations with the formation of a unit called Tilray Medical USA, Inc. The unit aims to introduce medical-grade cannabis products in targeted therapeutic formats, the company said.</p><p>“This action [executive order] aligns regulation with a vast body of scientific and medical data supporting cannabis medical use and safety, economic progress, and a healthcare-focused framework, while creating a more credible foundation for medical cannabis research, clinical development, and regulatory clarity,” Tilray CEO Irwin D. Simon said.</p><h2 class="st-heading-2">Other Cannabis Firms Respond To Policy Change</h2><p>Cresco Labs applauded the executive order terming it a “cultural turning point” and a “historic shift.” Trulieve too applauded the decision while <a href="https://stocktwits.com/symbol/SMG">Scotts Miracle-Gro</a> expressed support highlighting that 39 states already legalize cannabis in some form. Scotts expects to combine its Hawthorne Gardening company subsidiary, which provides nutrients, lighting and other supplies to legal cannabis growing operations, with a cannabis company in 2026.</p><p><a href="https://stocktwits.com/symbol/HITI">High Tide</a> said that it is exploring structures that would allow it to expand its Canna Cabana retail brand into the U.S. through licensing.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TLRY">TLRY</a> and <a href="https://stocktwits.com/symbol/CGC">CGC</a> trended in the ‘extremely bullish’ territory at the time of writing. Sentiment around <a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF</a> (MSOS), which tracks American operators, followed suit.</p><p>TLRY and CGC shares are down 8% and 39% this year, respectively.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-eyes-ex-tesla-employee-sterling-anderson-as-potential-successor-to-ceo-mary-barra-report/cLegDrmRErL">General Motors Eyes Ex-Tesla Employee Sterling Anderson As Potential Successor To CEO Mary Barra: Report</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Cannabis plants grow in the greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. (Photo by Drew Angerer/Getty Images)

Tilray, Aurora Cannabis, Trulieve Pull Back After Trump Marijuana Order Rally Runs Out Of Steam

Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research.

Equity

Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide, but is instead aimed at improving medical marijuana and cannabidiol research.


Cannabis ETFs Soar Double-Digits on Friday: Here's Why

Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.

Trump Moves A Step Closer To Reclassifying Marijuana As A Less Dangerous Drug — A Breakout Moment For Weed Industry?

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

<ul class="summary-bullets"><li>Bloomberg reported that the Centers for Medicare &amp; Medicaid Services (CMS), which runs the Medicare program, is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;</li><li>MSOS and YOLO, two key cannabis sector-focused funds, gained 3.4% and 2.7%, respectively.</li><li>The Trump administration seems to be backing cannabis as an industry, following its previous comments regarding CBD and reclassifying marijuana.</li></ul><p>Cannabis&nbsp;stocks advanced on Wednesday following a report speculating that certain U.S Medicare patients could soon be eligible to receive coverage for CBD under a new initiative.</p><p>CBD, or cannabidiol, is a compound found in cannabis and used to treat sleep disorders, anxiety, pain, and inflammation. Some research suggests it may also treat cancer symptoms. The drug is sold as gummies, pet treats, and skincare supplements.</p><h2 class="st-heading-2"><strong>Cannabis Stocks Rally</strong></h2><p>Tilray Brands’ shares rose 4.8%, while the over-the-counter stocks of Curaleaf Holdings, Trulieve Cannabis, and Green Thumb Industries gained between 2% to 5.6%. Shares of Innovative Industrial Properties, a real estate investment trust (REIT) that buys and leases specialized cannabis cultivation facilities, rose 1.1%.</p><p>On Stocktwits, the retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/TLRY">TLRY</a> shifted to ‘extremely bullish’ from ‘bullish,’ while that for&nbsp;<a href="https://stocktwits.com/symbol/CURLF">CURLF</a> shifted to ‘bullish’ from ‘neutral.’ The sentiment was ‘bullish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">GTBIF</a>, and ‘bearish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">TCNNF</a> and&nbsp;<a href="https://stocktwits.com/symbol/IIPR">IIPR</a> as of the last reading.&nbsp;</p><p>The&nbsp;<a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF (MSOS)</a>, which tracks U.S. cannabis companies exclusively, and the&nbsp;<a href="https://stocktwits.com/symbol/YOLO">AdvisorShares Pure Cannabis ETF (YOLO)</a>, which also tracks overseas companies and cannabis-adjacent businesses, rose 3.4% and 2.7%, respectively.</p><h2 class="st-heading-2"><strong>CMS Initaitive</strong></h2><p>The rally came after Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-26/medicare-to-test-making-cbd-treatment-available-for-seniors">reported</a> that the Centers for Medicare &amp; Medicaid Services (CMS) is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;</p><p>Details of the proposed program aren’t available, but an early version of the plan focused on seniors in oncology and palliative care settings, according to a summary viewed by the news agency.</p><p>Unnamed sources told Bloomberg that Howard Kessler, a payments financier who has advocated for expanded CBD access, met with Health and Human Services Secretary Robert F. Kennedy Jr. about the issue last month</p><h2 class="st-heading-2"><strong>A Trump Boost?</strong></h2><p>The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. Hemp-derived cannabidiol (CBD) could "revolutionize senior healthcare" by slowing disease progression and serving as an alternative to prescription drugs, Trump had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-cannabis-stocks-lose-high-premarket-after-surge-triggered-by-trumps-post/chDDTJ9R3BB">said</a> in a video post in September.</p><p>The previous month, Trump said his administration was weighing a move to reclassify marijuana as a less dangerous drug under federal law.</p><p>That said, doubts over cannabis efficacy in healthcare remain. A&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836267">recent study</a> funded by the Food and Drug Administration suggested that prolonged use of CBD may cause liver toxicity, while other research suggests it can interfere with other medications, harm male reproductive health, and pose potential risks to children and pregnant women.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/holiday-shopping-could-soar-to-a-record-1-trillion-this-year-with-online-spending-blasting-to-new-highs/cL5eLqVREW6">Holiday Shopping Could Soar To A Record $1 Trillion This Year, With Online Spending Blasting To New Highs</a></p>

Tilray, IIPR, Trulieve, Other Cannabis Stocks Rally On Report Of Government Considering Adding CBD Treatment For Medicare Patients  

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. 

<ul class="summary-bullets"><li>The provision bans online, gas station, and corner store sales of intoxicating hemp products, including delta-8, starting in 2026.</li><li>The rules are set to take effect in 2026, creating new compliance requirements for producers and retailers.</li><li>Tilray criticized the legislation, warning that it may prompt consumers to turn to unregulated alternatives.</li></ul><p>Cannabis stocks were trading lower in afternoon trade on Thursday amid broader weakness in the equities market after the U.S. government funding bill to end the shutdown included language tightening rules on hemp-derived THC products.</p><p>Tilray Brands (TLRY) and Canopy Growth (CGC) shares fell more than 7%, while Green Thumb Industries (GTBIF) dipped 2.4%. Retail sentiment was ‘bearish’ around&nbsp;<a href="https://stocktwits.com/symbol/TLRY">Tilray’s stock</a>, according to Stocktwits data.&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">Green Thumb Industries’ stock</a> saw retail sentiment trending in ‘bullish’ territory over the past day, while retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/CGC">Canopy Growth’s stock</a> trended in the ‘extremely bullish’ zone.</p><h2 class="st-heading-2">New Hemp Rules Take Effect in 2026</h2><p>The funding legislation includes a provision banning the “unregulated sale of intoxicating hemp-based or hemp-derived products, including delta-8, from being sold online, in gas stations, and corner stores,” according to a Senate Appropriations Committee summary. The rules are set to take effect in 2026, creating new compliance requirements for producers and retailers.</p><p>Tilray criticized the move, calling it a “misguided” step that could push consumers toward unregulated alternatives. “Prohibition and overly restrictive measures do not work,” the company said in a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tilray.com/news-releases/news-release-details/tilray-brands-condemns-misguided-prohibitionist-measures-and">statement</a> on Wednesday.</p><h2 class="st-heading-2">Retail Traders See Upside</h2><p>One Stocktwits user noted that the federal hemp ban increases the upside and that it’s a good opportunity to buy the dip.</p><p><stembedurl>https://stocktwits.com/techvested/message/636064141</stembedurl></p><p>Another user highlighted the optimism of investors buying cheap shares, anticipating that a rescheduling announcement for cannabis may be on the horizon later this year or next year.&nbsp;</p><p><stembedurl>https://stocktwits.com/Thumbszilla/message/636090102</stembedurl></p><p>The regulatory changes also weighed on broader cannabis-focused exchange-traded funds. AdvisorShares Pure U.S. Cannabis ETF (<a href="https://stocktwits.com/symbol/MSOS">MSOS</a>) fell more than 5% in afternoon trade on Thursday, while the Cambria Cannabis ETF (<a href="https://stocktwits.com/symbol/TOKE">TOKE</a>) dropped 1.4%.&nbsp;</p><p><strong>Read also:&nbsp;</strong><a href="https://stocktwits.com/news-articles/markets/equity/circle-stock-gains-after-jpmorgan-turns-bullish-cathie-woods-ark-invest-buys-the-dip/cLP9RYgRE3X"><strong>Circle Stock Gains Pre-Market After JPMorgan Turns Bullish, Cathie Wood’s Ark Invest Buys The Dip</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Cannabis Stocks Drop As Shutdown Deal Tightens Hemp-THC Rules

The U.S. government funding bill to end the shutdown included language tightening rules on hemp-derived THC products.

Trade War or Not, Specific Industry ETFs Are in Sweet Spots

Trade war jitters rise, but ETFs like MSOS, SILJ, SGDJ, BBC, WISE & CTEX shine on solid fundamentals, offering either safe havens or growth potential.

From Loss to Lift-Off: Marijuana ETFs Rebound on Legalization Prospects 

Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism. 

Best-Performing ETFs of Last Week

Despite the U.S. govt shutdown, ETFs like MSOS, WEED, HOOW, HYDR, BKCH & SATO surged last week, driven by rallies in cannabis, hydrogen & crypto.

Current Price	$4.76
Prev Close	$4.72
Open	$4.77
Dividend Yield	N/A
50-Day Moving Average	$4.25
Beta	N/A
Avg. Volume	8.26M
PE Ratio	N/A

52-Week High	$7.25
52-Week Low	$2.02
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

MSOS
AdvisorShares Pure US Cannabis ETF

Feed

News

Sentiment

Fundamentals

Info

Latest MSOS News

MSOSAdvisorShares Pure US Cannabis ETF